Stockhub

Eledon Pharmaceuticals, Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

23 September 2022

  • curprev 21:3221:32, 23 September 2022 95.149.241.133 talk 880 bytes +880 Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is i..."
Retrieved from "https://stockhub.co/research/Eledon_Pharmaceuticals,_Inc."